A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia
Completed
BioMarin Pharmaceutical
Phase 2
2014-01-13
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children
with achondroplasia. The primary objective is to assess the safety and tolerability of daily
BMN 111 administered to children with achondroplasia.
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
Active, not recruiting
BioMarin Pharmaceutical
Phase 2
2016-01-26
This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety,
Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective
is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in
children with ACH who have completed two years of treatment in the 111-202 study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
